Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)
Close on Nov 17, 2026Market cap $3.06BP/E –Yield –
Xeris Biopharma EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Xeris Biopharma's EV/EBITDA was 79.1× on Nov 11, 2026, against 119.1× a year earlier.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 79.1× | −50.0 |
| 2025 | Dec 31, 2025 | 129.1× | – |
See a number that looks wrong?